Delighted to share this great news from IIT Kanpur. Today, we licensed a groundbreaking gene therapy technology to Reliance Life Sciences Private Limited. This will lead to significant advancement in developing treatments for many hereditary eye diseases. This breakthrough is likely to potentially improve addressing genetic disorders in ways never seen before. 

Developed by Prof. Jayandharan Rao and Mr. Shubham Maurya from the Department of Biological Sciences and Bioengineering, the patented technology involves using Adeno-associated virus (AAV) based gene therapy vectors which are optimized for their gene delivery potential by modifying amino acids in the viral coat protein. 

Gene therapy using viral vectors has recently emerged as a potent tool in the field of molecular medicine and the licensing of the technology developed at IIT Kanpur to Reliance Life Sciences represents a significant step forward in developing innovative solutions to address unmet medical needs.